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Abstract
Objective: Preventing unintended pregnancy among HIV-positive women constitutes a critical and cost-effective approach
to primary prevention of mother-to-child transmission of HIV and is a global public health priority for addressing the
desperate state of maternal and child health in HIV hyper-endemic settings. We sought to investigate whether the
prevalence of contraceptive use and method preferences varied by HIV status and receipt of highly active antiretroviral
therapy (HAART) among women in Soweto, South Africa.
Methods: We used survey data from 563 sexually active, non-pregnant women (18–44 years) recruited from the Perinatal
HIV Research Unit in Soweto (May–December, 2007); 171 women were HIV-positive and receiving HAART (median duration
of use = 31 months; IQR = 28, 33), 178 were HIV-positive and HAART-naı¨ve, and 214 were HIV-negative. Medical record
review was conducted to confirm HIV status and clinical variables. Logistic regression models estimated adjusted
associations between HIV status, receipt of HAART, and contraceptive use.
Results: Overall, 78% of women reported using contraception, with significant variation by HIV status: 86% of HAART users,
82% of HAART-naı¨ve women, and 69% of HIV-negative women (p,0.0001). In adjusted models, compared with HIV-
negative women, women receiving HAART were significantly more likely to use contraception while HAART-naı¨ve women
were non-significantly more likely (AOR: 2.40; 95% CI: 1.25, 4.62 and AOR: 1.59; 95% CI: 0.88, 2.85; respectively). Among HIV-
positive women, HAART users were non-significantly more likely to use contraception compared with HAART-naı¨ve women
(AOR: 1.55; 95% CI: 0.84, 2.88). Similar patterns held for specific use of barrier (primarily male condoms), permanent, and
dual protection contraceptive methods.
Conclusion: Among HIV-positive women receiving HAART, the observed higher prevalence of contraceptive use overall and
condoms in particular promises to yield fewer unintended pregnancies and reduced risks of vertical and sexual HIV
transmission. These findings highlight the potential of integrated HIV and reproductive health services to positively impact
maternal, partner, and child health.
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Introduction
Nearly 80% of the world’s 15.5 million HIV-infected women
live in sub-Saharan Africa, where heterosexual intercourse is the
primary mode of HIV transmission [1]. Each year, these women
experience over 1.4 million pregnancies [2], of which an estimated
50–84% are unintended [3,4,5]. Many of these pregnancies
contribute to distressing adverse outcomes for women, children,
and their families. Every year, nearly 350,000 infants are infected
with HIV via mother-to-child transmission (MTCT) [1]. Maternal
mortality, the world’s worst health inequity, is exacerbated in the
context of HIV [6], with recent reports indicating that maternal
deaths have increased considerably in regions of high HIV
prevalence [7]. In addition, across sub-Saharan Africa there are an
estimated 8.9 million maternal orphans due to HIV-associated
mortality [8].
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Addressing the current desperate state of maternal and child
health in sub-Saharan Africa is a global public health priority
embodied in Millennium Development Goals (MDGs) 4 (reducing
child mortality) and 5 (improving maternal and reproductive
health) [9]. Central to achieving these goals is the prevention of
unintended pregnancy through increasing access to and use of
effective contraception [10].
Among women living with HIV infection, the provision of
contraceptive services to prevent unintended pregnancy is also a
critical [11] but largely neglected strategy to prevent mother-to-
child-transmission (PMTCT) of the virus [12]. A recent cost-
effectiveness study showed that a PMTCT strategy focused on
increasing contraception among HIV-positive women could avert
29% more HIV-positive births than prophylactic nevirapine alone,
at the same level of expenditure [13]. However, the prevailing
under-emphasis of reproductive health within HIV programming
remains evident in the numbers: unwanted fertility among women
living with HIV is estimated to account for 25% of infant
infections (nearly 90,000 MTCT incidents every year) and 20% of
infant mortality [14].
The little that is known about the prevalence and types of
contraceptive use among HIV-infected women in sub-Saharan
Africa originates from studies conducted prior to the widespread
availability of highly active antiretroviral therapy (HAART), the
standard of HIV treatment [3,15,16,17]. This is due, in part, to
the recency of the population-level HAART scale-up effort in the
region [18]. By increasing life expectancy [19,20,21], decreasing
morbidity [20,22], and reducing vertical [23] and sexual [24]
transmission risks, expanding access to HAART is dramatically
reducing the health risks and barriers to reproduction among
HIV-affected individuals and couples. This emerging reality of
HIV as a manageable chronic disease, with HIV-infected
individuals anticipated to live well into (and past) their peak
reproductive years, has highlighted the importance of assessing the
potential behavioral and biological impacts of HAART on
contraceptive use, safety, and efficacy [25,26,27,28,29,30,31,32].
Given the HIV hyper-endemic context of reproduction in
Soweto, South Africa [1,33], the primary objective of this study
was to assess the prevalence of contraceptive use and to determine
whether contraceptive use varies according to HIV serostatus and
use and duration of HAART among sexually active women aged
18–44 years. A secondary objective was to determine the types of
contraceptive methods used (including barrier, hormonal, perma-
nent, and dual protection methods) and whether contraceptive
method preferences vary by HIV status and HAART use. This
research was conducted within Kaida et al’s conceptual framework
of the potential impact of HAART on fertility in sub-Saharan
Africa [26], where HAART use is hypothesized to reduce
individuals’ perceived risk of HIV transmission and disease
progression, ease concerns about the risks of reproduction, and
alter contraceptive use patterns. As such, we hypothesized that
HIV-positive women receiving HAART would be less likely to use
contraception compared with HIV-positive women not receiving
HAART, with increasing duration of HAART use associated with
incrementally lower contraceptive use. In addition, we hypothe-
sized that contraceptive prevalence among HIV-positive women
receiving HAART and HIV-negative women would be similar.
Methods
Study Setting
With 5.5 million HIV-infected residents, South Africa is the
country with the world’s largest absolute number of people living
with HIV [1]. The national adult (aged 15–49 years) HIV
prevalence is 19% and the antenatal HIV prevalence is 30% [1].
The South African epidemic is highly feminized as women
account for 60% of all infected adults and among 15–24 year olds,
women account for 90% of incident HIV infections [34]. HIV
prevalence in the study site, Soweto, an urban township of
Johannesburg, is among the highest in the country [33].
Each year an estimated 220,000 women living with HIV in
South Africa become pregnant [2]. Although coverage of
prophylactic antiretroviral therapy to prevent MTCT increased
from 15% to 73% between 2004 and 2008 [2], recent estimates
report that over 64,000 infants are infected with HIV via MTCT
each year [35]. Combination antiretroviral therapy became
available in South Africa’s public sector clinics in 2004 and by
the end of 2008 an estimated 700 000 adults were receiving
HAART, an antiretroviral therapy coverage of 31% [2].
Effective contraceptive methods, including injectables (Nur-
Isterate and Depo Provera), oral contraceptive pills, the intrauterine
device (IUD), condoms, and male and female sterilization, are
available at no-cost in government health centres throughout
Soweto. Elective termination of pregnancy is legal in South Africa
and available at no-cost up to 12 weeks gestation.
This study was conducted at the Perinatal HIV Research Unit
(PHRU), a large clinical and research site housed within one of the
world’s largest hospitals: Chris Hani Baragwanath Hospital in
Soweto. The PHRU sees over 5 000 adult visits monthly and
provides antiretroviral therapy and clinical care to medically-
eligible HIV-positive individuals and ongoing wellness care for
those not yet eligible for HAART. The PHRU also operates a
Voluntary Counseling and Testing (VCT) centre. All PHRU
services (including HIV prevention, testing, treatment and care
and family planning) are provided free-of-charge. Since April
2006, onsite no-cost family planning services have been available
to HIV-positive women accessing antiretroviral therapy at the
PHRU. These services offer barrier, oral, and injectable
contraceptive methods as well as family planning counseling from
a trained family planning nurse. Treatment-naı¨ve HIV-positive
women may also access family planning services from the PHRU,
however, they are not routinely queried about their contraceptive
use during regular clinical follow-up. The PHRU primarily serves
residents of Soweto.
Study design
This analysis is based on cross-sectional survey data of HIV-
positive (HAART receiving and HAART-naı¨ve) and HIV-
negative women seeking services at the PHRU. A medical chart
review was also conducted to confirm HIV serology and HAART
use history of HIV-positive women.
Eligibility criteria
To be eligible to participate in the overall study, women were
required to be 18–49 years of age, attending a PHRU clinic,
residing in Soweto, competent to give informed consent, and
willing to allow medical record review for the purposes of
confirming HIV status and HAART history. We considered
women to be HAART users if they had been receiving HAART
for at least one month. We considered women to be HAART-
naı¨ve if they had never taken HAART.
Study Sample
We enrolled 751 women, including 253 HIV-positive women
receiving HAART, 249 HIV-positive but HAART-naı¨ve women,
and 249 HIV-negative women. This sampling strategy provided
one case group (HAART users) and two comparison groups
(HAART-naı¨ve and HIV-negative women).
HIV, HAART, and Contraception
PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e13868
HAART users were sampled from the PHRU’s President’s
Emergency Plan for AIDS Relief (PEPFAR) Clinic, which has
provided free antiretroviral therapy to medically eligible patients
since July 2004. Currently, the PEPFAR clinic has over 1,000
patients receiving HAART, 75% of who are female. PEPFAR
patients are followed-up every three months and generally receive
one of two standard HAART regimens. Regimen 1 consists of
stavudine (d4T), lamivudine (3TC), and efavirenz (EFV) or
nevirapine (NVP). Regimen 2 consists of zidovudine (AZT),
didanosine (ddI), and lopinavir/ritonavir (LPV/r) [36].
HIV-positive HAART-naı¨ve women were sampled from the
PHRU’s Wellness Clinic, initiated in January 2003 with the goal of
providing preventive care to HIV-positive individuals. Wellness
patients are followed-up approximately every six months. When
patients become medically eligible for HAART, they are referred
to the PEPFAR clinic or to one of the nearby government ART
clinics. There are approximately 3,000 active patients in the
Wellness Clinic.
HIV-negative women were sampled from the PHRU’s VCT
clinic, which was initiated in mid-2002 and sees approximately
400 people per month. Testing is conducted onsite during visits
that last an average of two hours. Approximately 65% of attendees
are women and 30% of all attendees test HIV-positive.
For this analysis on contraceptive use, we restricted the study
sample to women aged 18–44 years who were currently sexually
active (i.e., reported sexual activity in the previous six months), not
currently pregnant, and pre-menopausal as per self-report). This
was done to enhance the comparability of findings with other
studies investigating reproductive and sexual health among HIV-
positive populations. The restriction yielded an analytic sample of
563 women (75% of total sample), including 171 women on
HAART, 178 HAART-naı¨ve women, and 214 HIV-negative
women.
Data Collection
Every female patient attending the PEPFAR Clinic and the
VCT clinic was consecutively approached by a research assistant
to assess eligibility and interest in participating in the study. Since
many more women attend the Wellness Clinic, a list was made of
chart numbers of women attending the clinic each day. A random
sample of chart numbers (40% of the total number of charts
present) was then drawn and the corresponding women were
approached to assess eligibility and interest in participating in the
study.
After confirming eligibility and seeking written informed
consent, all participants were asked to complete a 15–25 minute
interviewer-administered questionnaire in English. The study
interviewers were multilingual and trained to ensure accurate
and consistent translation of the questionnaire if required or
requested by the participant. Pilot testing of 45 women revealed
that women were able to understand and answer the question-
naire. Pilot testing helped to ensure a more comprehensive list of
responses were available for structured questions and that terms
such as ‘‘sexual intercourse’’ were defined to refer specifically to
‘‘vaginal sex between a man and a woman’’. Approximately 12
women were interviewed daily by three trained research assistants
between May and December 2007. Research assistants were
women from the local community who had previous research
experience and were recent Social Sciences’ graduates of a local
university. Interviewers were supervised by an experienced
research nurse. Two research nurses with HIV training conducted
the medical record review. Participants were given transport
reimbursement as compensation.
Data Collection Instruments
The questionnaire assessed socio-demographic characteristics;
HIV status, diagnosis, and treatment; clinical stage of disease;
HAART history; fertility intentions; fertility history; contraceptive
practices; and sexual history. The survey instrument was
developed from a validated questionnaire used in an earlier pilot
study [37].
We reviewed medical records of HIV-positive women to
confirm HIV status and HAART history, and to obtain clinical
data including CD4 cell counts and WHO stage of disease. Viral
load measures were only available for women receiving HAART
as only patients receiving treatment in the PEPFAR clinic undergo
viral load testing.
Measures
The primary outcome was self-reported contraceptive use in the
previous six months. Contraceptive methods queried included
male and female condoms (restricted to those reporting ‘‘Always’’
use), injections (depomedroxyprogesterone acetate (DMPA) or norethisterone
enantate), oral contraceptive pills, diaphragm, intrauterine devices
(IUD), female tubal ligation, hysterectomy, and male partner
sterilization. In assessing the contraceptive method profile, dual
protection was defined as use of both a barrier contraceptive
method (primarily the male condom) and use of a hormonal or
permanent contraceptive method [38].
The primary explanatory variables were HIV status and current
receipt of HAART. Covariates included age, education, employ-
ment, household income, current sexual partnership, HIV status of
regular sexual partners, parity, number of living children, fertility
intentions, and HIV clinical variables.
Statistical Analysis
We computed and compared the prevalence of contraceptive
use between HIV-positive women and HIV-negative women
overall and then between each of the three groups of women. We
conducted two separate models to measure the presence and
strength of the association between HAART use and the odds of
contraceptive use, controlling for covariates. The first model
compared HAART users and HAART-naı¨ve women to HIV-
negative women. The second model compared HAART users to
HAART-naı¨ve women and allowed adjustment for HIV-associat-
ed clinical characteristics.
In both models, univariate analyses were used to assess the
relationship between HIV status, receipt of HAART, contracep-
tive use, and covariates. Differences in contraceptive use between
groups are reported using Pearson’s chi-squared test (for
categorical variables) and ANOVA, or Student’s independent t-
test (for continuous variables). After testing for co-linearity (using
Spearman’s rho (r)) [39] and interaction [40], all covariates with
significant associations in the univariate analysis were included in
multivariate logistic regression models to obtain adjusted estimates
of the association between HIV status, receipt of HAART, and
contraceptive use. Age was forced into both multivariate models
regardless of its univariate associations. All statistical tests were
two-sided and considered significant at a= 0.05.
Among women who reported using contraception, we analyzed
types of methods used by women in each of the three groups and
overall. In addition to reporting use of each contraceptive method
individually, we collapsed the data into four mutually exclusive
groups including ‘‘Use of dual protection’’, ‘‘Consistent condom
use only’’, ‘‘Use of Hormonal/Permanent method only’’, and
‘‘Not using any contraceptive method’’ and tested for differences
by HIV and HAART use status using Pearson’s chi-squared test.
HIV, HAART, and Contraception
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e13868
We assessed the association between duration of HAART use
and prevalence of contraceptive use using Pearson’s test for trend.
HAART-naı¨ve women were included in the ‘‘0 months on
HAART’’ category.
Sub-Analyses
We conducted the same analyses described above but restricted
our sample to women aged 18–34 years to investigate the potential
impact of differences in mean baseline age between HIV-positive
and HIV-negative women in our study. This age group
corresponds with the peak childbearing years among women in
South Africa [41].
Ethics Statement
All participants provided voluntary informed consent and all
procedures were approved by the Human Research Ethics
Committee of the University of the Witwatersrand, the University
of British Columbia Health Research Ethics Board, the Simon
Fraser University Office of Research Ethics, and the University of
California San Diego Institutional Review Board. Information
letters and consent forms were available in English and two local
languages (isi-Zulu and Sesotho) to ensure comprehensive
understanding of the study objectives, potential risks, and benefits.
Results
Of 801 women approached for participation, 751 consented,
completed the questionnaire, and underwent medical record
review (participation rate = 94%). This analysis was restricted to
563 sexually active, non-pregnant women aged 18–44 years.
Baseline characteristics
As shown in Table 1, there were differences in baseline
characteristics by HIV and HAART use status. Mean age was 30
years [SD = 6.7], however, HIV-negative women were significantly
younger than HIV-positive women. Half of the women had less
than a grade 12 education, 62% were unemployed, and 71% had a
monthly household income less than 3,000 ZAR ($380 USD).
Nearly one-quarter (23%) reported that her primary sexual partner
was HIV-positive, 29% reported that he was HIV-negative, and
42% did not know her partner’s HIV status. Mean parity was 1.5
[SD = 1.2] and 44% of women had two or more living children.
Nearly half (45%) reported intent to have more children.
Among HIV-positive women (n = 349), mean time since first HIV
diagnosis was 59.7 months [SD = 35.4]. Half had recent CD4 counts
$350 cells/mm3 (mean recent CD4 = 376.8 [SD = 208]) and 12%
had nadir CD4 counts ,50 cells/mm3 (mean nadir CD4 = 212.7
[SD = 166]). Nearly all women were in WHO Stage of Disease I or
II (98%) and 95% had disclosed their HIV status to someone.
Among HAART users (n = 171), median duration of HAART
use was 31 months [IQR: 28, 33], ranging from one to 89 months.
Eighty percent of HAART users with recorded viral load measures
were virally suppressed (,50 copies/ml).
Prevalence of contraceptive use
Overall contraceptive prevalence was 78%. This varied
significantly by HIV status with 84% of HIV-positive women
(including 86% of HAART users and 82% of HAART-naı¨ve
women) and 69% of HIV-negative women reporting current
contraceptive use (p,0.0001).
Types of contraceptive methods used
Contraceptive method preferences are shown in Table 2. Part
(a) of Table 2 shows mutually exclusive groups of contraceptive
users. As shown, HIV-positive women overall were significantly
more likely to use dual protection compared with HIV-negative
women (33% and 14%, respectively). Much of this difference was
accounted for by HAART users, of whom 40% reported using
dual protection compared with 24% of HAART-naı¨ve women
and 14% of HIV-negative women. HAART users were also
significantly more likely to report using condoms (with or without
hormonal/permanent methods) (68%) and hormonal/permanent
methods (with or without condoms) (58%) compared with
HAART-naı¨ve and HIV-negative women (p,0.0001).
Of the 411 women reporting contraceptive use (Table 2 part
(b)), 56% used hormonal contraception, 69% used barrier
methods (mainly the male condom), and 7% used permanent
methods (i.e., hysterectomy and/or female sterilization) with
significant differences by HIV status and HAART use. Across
all three groups, hormonal contraceptive users utilised injectables
more commonly than oral contraceptives. HAART users were
significantly more likely to use condoms (79%), compared with
HAART-naı¨ve (72%) and HIV-negative (57%) women
(p = 0.0001). Higher proportions of HIV-positive women had a
tubal ligation or hysterectomy compared with HIV-negative
women (p = 0.014).
Univariate and Adjusted Analysis of Contraceptive use:
HAART users, HAART non-users, and HIV-negative
women
In the unadjusted analyses, many of the measured baseline
covariates were significantly associated with contraceptive use
(Table 3). Compared with HIV-negative women, HIV positive
women were significantly more likely to use contraception
(HAART users OR: 2.73; 95% CI: 1.62, 4.59; and HAART-
naı¨ve women OR: 2.04; 95% CI: 1.26, 3.29).
In adjusted analyses, compared with HIV-negative women,
HAART users remained significantly more likely to use contra-
ception (OR: 2.40; 95% CI: 1.25, 4.62) while non-HAART users
were non-significantly more likely to use contraception (OR: 1.59;
95% CI: 0.88, 2.85). Overall, HIV-positive women (combining
HAART users and HAART-naı¨ve women) had significantly
increased adjusted odds of 1.75 (95% CI: 1.02, 2.99) of using
contraception compared with HIV-negative women. Younger age,
having two or more living children, and expressing an intention
not to have (more) children also remained significantly associated
with contraceptive use.
Univariate and Adjusted Analysis: HIV-positive women
In the analyses restricted to HIV-positive women (table 4), the
unadjusted odds of reporting contraceptive use among HAART
users and HAART-naı¨ve women were not significantly different
(OR: 1.34; 95% CI: 0.75, 2.39). There were no significant
differences in contraceptive use by HIV clinical characteristics.
In adjusted analyses, HAART users were more likely than non-
users to report contraceptive use, however the difference was not
statistically significant (AOR: 1.55; 95% CI: 0.84, 2.88). Younger
age, having two or more living children, and expressing an
intention not to have more children remained most strongly
associated with contraceptive use.
Contraceptive use by duration of HAART use
There was no clear association between duration of HAART
use and prevalence of contraceptive use. The prevalence of
contraceptive use remained steady (between 82% and 92%) for all
lengths of time on HAART with the exception of women receiving
HAART between one and two years, who had the lowest
HIV, HAART, and Contraception
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Table 1. Baseline characteristics of HIV-positive (HAART users and HAART-naı¨ve) and HIV-negative women (aged 18–44 years,
currently sexually active and non-pregnant) in Soweto, South Africa (n = 563).
Variable
HAART users (n=171)
n (%)
HAART-naı¨ve (n=178)
n (%)
HIV-negative (n=214)
n (%)
Overall (n=563)
n (%) p-value¥
Mean Age (yrs) [SD] 33.7 [5.0] 32.3 [5.6] 25.3 [6.0] 30.0 [6.7] ,0.0001
Age Group (yrs) ,0.0001
18–24 4 (2%) 15 (8%) 119 (56%) 138 (25%)
25–29 30 (18%) 41 (23%) 43 (20%) 114 (20%)
30–34 66 (39%) 63 (36%) 37 (17%) 166 (30%)
35–39 43 (25%) 35 (20%) 7 (3%) 85 (15%)
40–44 27 (16%) 23 (13%) 8 (4%) 58 (10%)
Education ,0.0001
Less than Grade 12 114 (67%) 109 (61%) 60 (28%) 283 (50%)
Grade 12 or higher 56 (33%) 69 (39%) 154 (72%) 279 (50%)
Employment Status 0.0962
Employed 71 (42%) 75 (42%) 70 (33%) 216 (38%)
Unemployed 100 (58%) 103 (58%) 144 (67%) 347 (62%)
Household income (per month) ,0.0001
Less than 3000 ZAR 142 (83%) 146 (82%) 111 (52%) 399 (71%)
3,000 or more ZAR 16 (9%) 24 (13%) 65 (30%) 105 (19%)
Don’t know/Refused 13 (8%) 8 (4%) 38 (18%) 59 (10%)
Currently in a sexual relationship 0.6337
No 12 (7%) 16 (9%) 14 (7%) 42 (7%)
Yes 159 (93%) 162 (91%) 200 (93%) 521 (93%)
HIV status of regular sexual partner/husband ,0.0001
Don’t Know 64 (37%) 87 (49%) 83 (39%) 234 (42%)
HIV-negative 30 (18%) 22 (12%) 111 (52%) 163 (29%)
HIV-positive 69 (40%) 59 (33%) 2 (1%) 130 (23%)
Single 8 (5%) 10 (6%) 18 (8%) 36 (6%)
Mean parity [SD] 1.9 [1.1] 1.9 [1.2] 0.85 [0.9] 1.5 [1.2] ,0.0001
Number of living children ,0.0001
0 19 (11%) 19 (11%) 96 (45%) 134 (24%)
1 58 (34%) 56 (31%) 68 (32%) 182 (32%)
2 or more 94 (55%) 103 (58%) 50 (23%) 247 (44%)
Fertility Intentions
Yes 55 (32%) 55 (31%) 146 (68%) 256 (45%) ,0.0001
No 116 (68%) 123 (69%) 68 (32%) 307 (55%)
Mean # of months since HIV diagnosis [SD] 69.0 [36.3] 50.8 [32.1] N/A 59.7 [35.4] ,0.0001
Mean recent CD4 [SD] 405.7 [211.2] 349.4 [202.3] N/A 376.8 [208] 0.0117
Mean nadir CD4 [SD] 110.1 [98.9] 309.4 [157.6] N/A 212.7 [166] ,0.0001
WHO Stage of Disease 0.5267
Stage I/II 165 (98%) 173 (97%) N/A 338 (98%)
Stage III/IV 3 (2%) 5 (3%) 8 (2%)
Disclosed HIV status to anybody 0.0493
No 4 (2%) 12 (7%) N/A 16 (5%)
Yes 167 (98%) 166 (93%) 333 (95%)
Notes:
¥Differences between groups are reported using Pearson’s chi-squared test statistic (for categorical variables) and Student’s independent t-test or ANOVA (for
continuous variables); SD = Standard Deviation; N/A = Not Applicable.
doi:10.1371/journal.pone.0013868.t001
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prevalence of contraceptive use at 67% (Figure 1). However, as
there were few women receiving HAART for 1–2 years, the 95%
confidence interval on this estimate is very wide.
Sub-analyses
Contraceptive prevalence of young women (18–34 yrs, n = 420)
was similar to the overall sample and still varied significantly by
HIV and HAART use status: 88% of HAART users, 82% of
HAART-naı¨ve women, and 70% of HIV-negative young women
reported using contraception (p = 0.0007). In multivariate analyses
we found that the same variables associated with contraceptive use
in the overall sample were similarly associated with contraceptive
use among young women. Compared with HIV-negative women,
HAART users remained significantly more likely to use contra-
ception (AOR: 2.24; 95% CI: 1.05, 4.99) while HAART-naı¨ve
women were similarly likely to use contraception (AOR: 1.27,
95% CI: 0.65, 2.48) (data shown in Table S1).
Discussion
We found that HIV-positive women overall were significantly
more likely to use contraception compared with HIV-negative
women. In particular, and in contrast with our hypothesis, women
receiving HAART were significantly more likely to report
contraceptive use while HIV-positive HAART-naı¨ve women were
non-significantly more likely to use contraception compared with
HIV-negative women. Overall, over 80% of HIV-positive women
in our study reported contraceptive use, which falls within the
upper range reported for HIV-positive women elsewhere in sub-
Saharan Africa (46%–85%) [16,17,25,32,42,43]. Contraceptive
prevalence among HIV-negative women in our study was 69%,
which is highly comparable to estimates among women in the
general South African population [41].
Among HIV-positive women, our finding indicating non-
significantly higher prevalence of contraceptive use among
HAART users compared with HAART-naı¨ve women is broadly
consistent with recent findings from Uganda [25]. Other factors
associated with contraceptive use included younger age, having
two or more living children, and a lack of intention to have more
children, all of which are widely reported to influence contracep-
tive decision-making [17,25,44]. To the best of our knowledge, this
is the first study to show no significant change in prevalence of
contraceptive use by duration of HAART use.
The reasons for higher contraceptive prevalence among HIV-
positive women in general and HAART users in particular were
not directly explored in this study. However, an important possible
Table 2. Types of contraceptive methods used by HIV-positive (HAART users and HAART-naı¨ve) and HIV-negative women (aged
18-44 years, currently sexually active and non-pregnant) in Soweto, South Africa.
HIV-positive women
HIV-negative
women (n=214)
n (%)
Overall
(n = 563)
n (%) p-value1
HAART users
(n =171)
n (%)
HAART-naı¨ve
women (n=178)
n (%)
All HIV-positive
women (n=349)
n (%)
Contraceptive Prevalence 86% 82% 84% 69% 78% ,0.0001
(a) Mutually exclusive categories of type
of contraceptive method used:
,0.0001
Dual protection (Hormonal/permanent
method AND consistent condom use)
40% 24% 33% 14% 25%
Hormonal/Permanent method only 18% 23% 20% 30% 24%
Consistent condom use only 28% 35% 31% 25% 29%
Not using any contraceptive method 14% 18% 16% 31% 22%
(b) Method use among contraceptive
users (n=411)*: HIV-positive women
HIV-negative
women (n=148)
n (%)
Overall
(n = 441)
n (%) p-value1
HAART users
(n =146)
n (%)
HAART-naı¨ve
women (n=147)
n (%)
All HIV-positive
women (n=293)
n (%)
Hormonal Methods 88 (60%) 68 (47%) 156 (53%) 89 (60%) 245 (56%) 0.0211
Injections 82 (56%) 49 (34%) 131 (45%) 66 (45%) 197 (45%) 0.0007
Oral Contraceptive Pill 6 (4%) 19 (13%) 25 (9%) 23 (16%) 48 (11%) 0.0041
Barrier Methods 116 (79%) 105 (72%) 221 (75%) 85 (57%) 306 (69%) 0.0001
Consistent male condom use 116 (79%) 105 (72%) 221 (75%) 84 (57%) 305 (69%) 0.0001
Diaphragm 0 (0%) 0 (0%) 0 (0%) 1 (1%) 1 (,1%) n/a
Permanent methods 12 (8%) 20 (14%) 32 (11%) 4 (3%) 33 (7%) 0.0140
Hysterectomy 4 (3%) 5 (3%) 9 (3%) 0 (0%) 9 (2%) 0.0897
Female sterilization 8 (5%) 15 (10%) 23 (8%) 4 (3%) 27 (6%) 0.0234
Notes:
1p-value from chi-squared test statistics comparing proportions across three groups: HAART-users, HAART-naı¨ve, and HIV-negative women;
*Values may not total 100% because one woman may report using more than one method.
doi:10.1371/journal.pone.0013868.t002
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reason for the observed differences is that women receiving HIV
treatment and care have more regular contact with health care
professionals as a function of the clinical follow-up required to
monitor the health of HIV-positive individuals. During these
regular clinic visits, reproductive and sexual health issues are
raised and the opportunity to discuss and commence use of
contraception is presented. Among HIV-positive women receiving
HAART at the PHRU in particular, discussions about family
planning are incorporated into the regular clinical follow-up
routine of PEPFAR patients. Moreover, although contraceptive
methods are freely available at numerous public health sector sites
in Soweto, it is likely that HIV-positive women are benefitting
from longitudinal and integrated regular contact with the PHRU
(a non-governmental health care facility) versus the intermittent
contact with government clinics more commonly experienced by
women not receiving HIV treatment and care [41]. It may also be
likely that HIV-positive women opting and/or able to receive HIV
treatment and care may have higher levels of self-empowerment
than those not in care, which may contribute to higher rates of
contraceptive use [45]. Additional studies are required to explore
and determine the specific pathways that support higher
contraceptive use among women accessing HAART in this setting.
The empirical findings reported here are inconsistent with the
hypothesized effects of HAART described in our conceptual
framework [26]. It must be noted that this conceptual framework
was developed by reviewing literature from the very early days of
HAART scale-up initiatives in sub-Saharan Africa. Since then,
there has been extensive scale-up of treatment services: in 2008, an
Table 3. Univariate and adjusted analyses of variables associated with contraceptive use among HIV-positive (HAART users and
HAART-naı¨ve) and HIV-negative women (aged 18–44 years, currently sexually active and non-pregnant) in Soweto, South Africa
(n = 563).
Variable Contraceptive Use Crude OR Adjusted OR
No (%)
(n =122)
Yes (%)
(n=441) OR 95% CI AOR 95% CI
HIV and HAART Use Status
HIV-negative 66 (54%) 148 (34%) Ref. Ref. Ref. Ref.
HIV-positive, HAART-naı¨ve 32 (26%) 146 (33%) 2.04 1.26, 3.29 1.59 0.88, 2.85
HIV-positive, receiving HAART 24 (20%) 147 (33%) 2.73 1.62, 4.59 2.40 1.25, 4.62
Age (per increase in year) 29.0 [SD = 7.4] 30.3 [SD = 6.5] 1.03 1.00, 1.06 0.94 0.90, 0.98
Education
Less than Grade 12 45 (37%) 238 (54%) Ref. Ref. Ref. Ref.
Grade 12 or higher 77 (63%) 202 (46%) 0.50 0.33, 0.75 0.70 0.44, 1.13
Employment Status
Unemployed 67 (55%) 280 (63%) Ref. Ref. – –
Employed 55 (45%) 161 (37%) 0.70 0.47, 1.05
Household income (per month)
Less than 3000 ZAR 72 (59%) 327 (74%) Ref. Ref. Ref. Ref.
3,000 or more ZAR 33 (27%) 72 (16%) 0.48 0.30. 0.78 0.94 0.55, 1.63
DK/Refused 17 (14%) 42 (10%) 0.54 0.29, 1.01 0.73 0.37, 1.43
Currently in a sexual relationship
No 12 (10%) 30 (7%) Ref. Ref. – –
Yes 110 (90%) 411 (93%) 1.50 0.74, 3.02
HIV status of regular sexual partner/husband – –
Don’t Know 50 (41%) 184 (42%) Ref. Ref.
HIV-negative 42 (34%) 121 (27%) 0.78 0.49, 1.25
HIV-positive 22 (18%) 108 (25%) 1.33 0.77, 2.32
Single 8 (7%) 28 (6%) 0.95 0.41, 2.22
Number of living children
0 43 (35%) 91 (21%) Ref. Ref. Ref. Ref.
1 50 (41%) 132 (30%) 1.25 0.77, 2.03 1.01 0.59, 1.73
2+ 29 (24%) 218 (49%) 3.55 2.09, 6.04 2.39 1.17, 4.89
Fertility Intentions
Yes 81 (66%) 175 (40%) Ref. Ref. Ref. Ref.
No 41 (34%) 266 (60%) 3.03 1.96, 4.55 1.96 1.17, 3.29
Notes:
Ref. = Reference category.
SD = Standard Deviation.
doi:10.1371/journal.pone.0013868.t003
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Table 4. Univariate and adjusted analyses of variables associated with contraceptive use among HIV-positive women (aged 18–44
years, currently sexually active and non-pregnant) in Soweto, South Africa (n = 349).
Variable Contraceptive Use Crude OR Adjusted OR
No (%)
(n =56)
Yes (%)
(n=293) OR 95% CI OR 95% CI
HAART Use
HIV-positive, HAART-naı¨ve 32 (57%) 146 (50%) Ref. Ref. Ref. Ref.
HIV-positive, receiving HAART 24 (43%) 147 (50%) 1.34 0.75, 2.39 1.55 0.84, 2.88
Age (per increase in year) 33.3 [SD = 5.6] 32.9 [SD = 5.3] 0.99 0.94, 1.04 0.93 0.88 0.99
Education
Less than Grade 12 29 (52%) 194 (66%) Ref. Ref. Ref. Ref.
Grade 12 or higher 27 (48%) 98 (34%) 0.54 0.30, 0.97 0.62 0.33, 1.17
Employment Status
Unemployed 31 (55%) 172 (59%) Ref. Ref. – –
Employed 25 (45%) 121 (41%) 0.87 0.49, 1.56
Household income (per month)
Less than 3000 ZAR 44 (79%) 244 (83%) Ref. Ref. – –
3,000 or more ZAR 8 (14%) 32 (11%) 0.72 0.31, 1.67
DK/Refused 4 (7%) 17 (6%) 0.77 0.25, 2.39
Currently in a sexual relationship
No 5 (9%) 23 (8%) Ref. Ref. – –
Yes 51 (91%) 270 (92%) 1.15 0.42, 3.17
HIV status of regular sexual partner/husband – –
Don’t Know 25 (45%) 126 (43%) Ref. Ref.
HIV-negative 8 (14%) 44 (15%) 1.09 0.46, 2.60
HIV-positive 21 (38%) 107 (37%) 1.01 0.54, 1.91
Single 2 (4%) 16 (5%) 1.59 0.34, 7.34
Number of living children
0 11 (20%) 27 (9%) Ref. Ref. Ref. Ref.
1 27 (48%) 87 (30%) 1.31 0.58, 2.99 1.12 0.47, 2.65
2+ 18 (32%) 179 (61%) 4.05 1.73, 9.50 3.07 1.18, 7.96
Fertility Intentions
Yes 30 (54%) 80 (27%) Ref. Ref. Ref. Ref.
No 26 (46%) 213 (73%) 3.03 1.72, 5.56 2.22 1.15, 4.35
Mean # of months since HIV diagnosis [SD] 59.6 [SD = 33.1] 59.8 [SD = 35.9] 1.00 0.99, 1.01 – –
Recent CD4
,200 8 (14%) 54 (19%) Ref. Ref. – –
200 to ,350 22 (39%) 88 (30%) 0.59 0.25, 1.43
350 or greater 26 (46%) 148 (51%) 0.84 0.36, 1.97
Nadir CD4
,50 7 (13%) 36 (12%) Ref. Ref. – –
50 to ,200 22 (39%) 133 (46%) 1.18 0.47, 2.97
200 to ,350 15 (27%) 63 (22%) 0.82 0.31, 2.19
350 or greater 12 (21%) 58 (20%) 0.94 0.34, 2.61
WHO Stage of Disease
Stage I/II 55 (98%) 283 (98%) Ref. Ref. – –
Stage III/IV 1 (2%) 7 (2%) 1.36 0.17, 11.3
Disclosed HIV status to anybody
No 0 (0%) 16 (5%) N/A N/A – –
Yes 56 (100%) 277 (95%)
Notes:
Ref. = Reference category; SD = Standard Deviation; N/A = Not applicable.
doi:10.1371/journal.pone.0013868.t004
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estimated 2.9 million people in the region were receiving ART, a
30-fold increase since in the end of 2003 [2]. Thus, early findings
and initial hypotheses about the effects of HAART use on the
proximate and underlying determinants of fertility may be
incomplete, as they were indirectly predicated on the novelty
and scarcity of HAART availability. In particular, an important
feature inadequately considered in the conceptual model that
guided this research is the failure to consider sufficiently the degree
to which access to HIV treatment services would provide a
primary point of regular access to health care, in a way that was
not previously available to many women [41]. In addition, while
the framework addressed the actual receipt or non-receipt of
HAART at the individual level, other recent findings suggest that
the availability and accessibility of HIV treatment services in a
given community and the role of HAART optimism [46] may be
additionally relevant variables. Thus, while the framework remains
a useful tool for the development of hypotheses to guide future
research regarding the impact of HAART on contraceptive use,
our group is currently working to update it to include more
recently available empirical findings.
Contraceptive method preference may have implications for
both HIV transmission and unintended pregnancy risks and we
found important differences in the types of contraceptive methods
used by women in each of our three groups. While condoms are
recommended to prevent HIV transmission to uninfected sexual
partners, they are less effective than hormonal contraception and
sterilization at preventing pregnancy [38]. Overall, a substantial
proportion of women in this setting report relying exclusively on
the male condom for preventing pregnancy (29%). An additional
25% of women report using condoms in conjunction with a
hormonal/permanent method of contraception, resulting in over
half of our sample reporting consistent condom use with or
without another method. HAART users reported the highest
prevalence of consistent condom use. Indeed much of the
difference in contraceptive prevalence between our three groups
was accounted for by the significantly lower prevalence of condom
use among HIV-negative women. Only 39% of HIV-positive
women reported consistent condom use (with our without another
contraceptive method). While this prevalence is comparable to
condom use rates reported in South Africa overall [41], all of the
HIV-negative women in our study were currently sexually active,
over 40% do not know the HIV-status of their primary partner,
and over two-thirds desire (more) children. This observed pattern
highlights the concerning risk environment for HIV acquisition
among women of reproductive age in this hyper-endemic setting.
Unlike barrier methods, permanent and hormonal contracep-
tive methods are highly effective at preventing pregnancy but have
no role in the prevention of HIV transmission [38]. Overall, 7% of
women used permanent methods (hysterectomy and/or female
sterilization) with small differences by HIV status and HAART
use. The overall prevalence of sterilization is slightly lower than
reported rates from South African women in general [41].
Compared with HAART-naı¨ve women, HAART users were
more likely to use hormonal contraception, and uptake of DMPA
injectables exceeded oral contraceptive use. Reports from other
settings suggest that DMPA use is rising owing to its discretion and
convenient three-month dosing which corresponds with the
HAART follow-up schedule [47]. Higher uptake of progester-
one-only injectables in HAART users may also reflect provider
preference based on concerns about possible interactions between
HAART and estrogen-containing oral contraceptives [48].
Available guidelines advise that women receiving antiretroviral
agents should use alternative or additional methods of contracep-
tion, beyond oral contraceptives [48].
Figure 1. Percentage of HIV-positive women using contraception, by length of time on highly active antiretroviral therapy
(HAART): Soweto, South Africa (n=349).
doi:10.1371/journal.pone.0013868.g001
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There is no single method that can reliably assist HIV-positive
women who wish to avoid pregnancy and HIV transmission to
sero-discordant partners. Moreover, given concerns noted above
about potential interaction between hormonal contraception and
antiretroviral agents, dual protection is encouraged. In our study,
not only were HAART users significantly more likely to use
contraceptive methods overall, they were more likely than non-
HAART users and HIV-negative women to use dual protection.
Low prevalence of dual protection among HAART-naı¨ve women
(24%), with largely unsuppressed HIV viral load, reflects a
population at risk of transmitting HIV to sero-discordant partners
and, if they do become pregnant, are a population most requiring
initiation of antiretroviral prophylaxis through PMTCT services.
Overall, 14% of HAART users, 18% of HAART-naı¨ve women,
and 31% of HIV-negative women were not using any form of
contraceptive, suggesting risk for unintended pregnancy. A high
proportion of women were also unaware of their partner’s HIV
status (42% overall). As such, the risks of conception-related HIV
acquisition or transmission between sero-discordant couples are
serious and integrated HIV and sexual and reproductive health
services must be provided to help HIV-affected couples safely
achieve their fertility goals.
Limitations of this study must be acknowledged. First, the cross-
sectional nature of this analysis precludes us from determining
causality between the explanatory variable and the outcome,
particularly since contraceptive use, HIV status, and HAART use
were assessed at the same point in time. Although reverse causality
is considered unlikely (i.e., contraceptive use leading to HAART
use), longitudinal studies are needed to investigate this relationship
and would enable examination of changes in fertility intentions
and contraceptive use over time. Second, there is a risk of social
desirability bias whereby HIV-positive women may over-report
their contraceptive use (and condom use, in particular) because of
pressure from health workers and community members to practice
protected sex [49,50]. If over-reporting was differential, then our
effect estimates are likely somewhat inflated. We took precautions
against reporting bias by using standardized questions of
contraceptive use and employing non-clinic staff to conduct the
interviews. Third, there were important baseline differences
between the HIV-positive and HIV-negative women in our study,
a potential source of selection bias, which cannot be fully adjusted
for in the analyses. In particular, HIV-positive women in our study
were significantly older and age is a known predictor of
contraceptive use and is associated with a number of other
covariates (e.g., parity, education status). In an attempt to address
this limitation, we conducted a sub-analysis of contraceptive use
restricted to women less than 35 years of age. We found no
differences in the variables that predicted contraceptive use, nor
the magnitude of the associations. The results of the sub-analysis
suggest that our overall findings are robust, despite differences in
age at baseline. Finally, a quantitative analysis such as this fails to
capture the salient influence of cultural and gender dynamics on
contraceptive decision-making. Indeed, qualitative studies from
this setting have highlighted the importance of considering the real
and perceived side effects of contraceptives and partner influence
and status as mitigating factors influencing contraceptive decision-
making of HIV-positive women [4].
In conclusion, our results demonstrate that HIV-positive
women overall and women accessing HAART services in
particular, are more likely to use contraception overall, and more
likely to use barrier, permanent, and dual protection methods in
particular, compared with their HIV-negative and HAART-naı¨ve
counterparts. The contraceptive use profile of HIV-positive and
HIV-negative women in Soweto highlights the need for improved
integration of HIV testing, treatment, and care services with
reproductive and sexual health services, including the provision of
effective contraception. Through the prevention of unintended
pregnancy, integrated services are likely to benefit maternal and
child health, increase primary prevention of vertical transmission,
and decrease incidence of conception-related horizontal transmis-
sion to discordant sexual partners [51].
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